Literature DB >> 27803045

Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk.

Yu Yin1,2, Qingfu Zhang2,3, Hong Zhang2, Yiping He2, Jiaoti Huang4.   

Abstract

A new 30-gene signature has been described that separates prostate cancers of Gleason score ≤6 from those of Gleason score ≥8. It provides independent prognostic information for prostate cancers of intermediate risk (Gleason score of 7), which has the potential to stratify these patients into different risk groups. Clin Cancer Res; 23(1); 6-8. ©2016 AACRSee related article by Sinnott et al., p. 81. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2016        PMID： 27803045      PMCID： PMC5215130          DOI： 10.1158/1078-0432.CCR-16-2400

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Authors:  Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone
Journal:  Lancet Oncol       Date:  2011-03       Impact factor: 41.316

2.  Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology.

Authors:  Jesse D Le; Samuel Stephenson; Michelle Brugger; David Y Lu; Patricia Lieu; Geoffrey A Sonn; Shyam Natarajan; Frederick J Dorey; Jiaoti Huang; Daniel J A Margolis; Robert E Reiter; Leonard S Marks
Journal:  J Urol       Date:  2014-05-01       Impact factor: 7.450

3.  Outcomes of active surveillance for men with intermediate-risk prostate cancer.

Authors:  Matthew R Cooperberg; Janet E Cowan; Joan F Hilton; Adam C Reese; Harras B Zaid; Sima P Porten; Katsuto Shinohara; Maxwell V Meng; Kirsten L Greene; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-11-29       Impact factor: 44.544

4.  mRNA expression signature of Gleason grade predicts lethal prostate cancer.

Authors:  Kathryn L Penney; Jennifer A Sinnott; Katja Fall; Yudi Pawitan; Yujin Hoshida; Peter Kraft; Jennifer R Stark; Michelangelo Fiorentino; Sven Perner; Stephen Finn; Stefano Calza; Richard Flavin; Matthew L Freedman; Sunita Setlur; Howard D Sesso; Swen-Olof Andersson; Neil Martin; Philip W Kantoff; Jan-Erik Johansson; Hans-Olov Adami; Mark A Rubin; Massimo Loda; Todd R Golub; Ove Andrén; Meir J Stampfer; Lorelei A Mucci
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

Review 5.  Active surveillance for prostate cancer: a systematic review of the literature.

Authors:  Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway
Journal:  Eur Urol       Date:  2012-06-07       Impact factor: 20.096

6.  Prognostic Utility of a New mRNA Expression Signature of Gleason Score.

Authors:  Jennifer A Sinnott; Sam F Peisch; Svitlana Tyekucheva; Travis Gerke; Rosina Lis; Jennifer R Rider; Michelangelo Fiorentino; Meir J Stampfer; Lorelei A Mucci; Massimo Loda; Kathryn L Penney
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

7.  Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry.

Authors:  E David Crawford; Mark C Scholz; Ashok J Kar; Jeffrey E Fegan; Abebe Haregewoin; Rajesh R Kaldate; Michael K Brawer
Journal:  Curr Med Res Opin       Date:  2014-03-13       Impact factor: 2.580

8.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Authors:  R Jeffrey Karnes; Eric J Bergstralh; Elai Davicioni; Mercedeh Ghadessi; Christine Buerki; Anirban P Mitra; Anamaria Crisan; Nicholas Erho; Ismael A Vergara; Lucia L Lam; Rachel Carlson; Darby J S Thompson; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Timothy J Triche; Thomas Kollmeyer; Karla V Ballman; Peter C Black; George G Klee; Robert B Jenkins
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

9.  Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens.

Authors:  Beatrice S Knudsen; Hyung L Kim; Nicholas Erho; Heesun Shin; Mohammed Alshalalfa; Lucia L C Lam; Imelda Tenggara; Karen Chadwich; Theo Van Der Kwast; Neil Fleshner; Elai Davicioni; Peter R Carroll; Matthew R Cooperberg; June M Chan; Jeffry P Simko
Journal:  J Mol Diagn       Date:  2016-03-03       Impact factor: 5.568

10.  A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Authors:  Eric A Klein; Matthew R Cooperberg; Cristina Magi-Galluzzi; Jeffry P Simko; Sara M Falzarano; Tara Maddala; June M Chan; Jianbo Li; Janet E Cowan; Athanasios C Tsiatis; Diana B Cherbavaz; Robert J Pelham; Imelda Tenggara-Hunter; Frederick L Baehner; Dejan Knezevic; Phillip G Febbo; Steven Shak; Michael W Kattan; Mark Lee; Peter R Carroll
Journal:  Eur Urol       Date:  2014-05-16       Impact factor: 20.096
  10 in total
  9 in total

Review 1.  Role of steroid receptor and coregulator mutations in hormone-dependent cancers.

Authors:  Anna C Groner; Myles Brown
Journal:  J Clin Invest       Date:  2017-04-03       Impact factor: 14.808

Review 2.  The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.

Authors:  Ariel A Schulman; Christina Sze; Efrat Tsivian; Rajan T Gupta; Judd W Moul; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

3.  Identification of seven long noncoding RNAs signature for prediction of biochemical recurrence in prostate cancer.

Authors:  Ning Shao; Yao Zhu; Fang-Ning Wan; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2019 Nov-Dec       Impact factor: 3.285

4.  Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis.

Authors:  Peng Zhang; Xiaodong Tan; Daoqiang Zhang; Qi Gong; Xuefeng Zhang
Journal:  PLoS One       Date:  2021-05-04       Impact factor: 3.240

5.  Gene Expression Analysis Reveals Prognostic Biomarkers of the Tyrosine Metabolism Reprogramming Pathway for Prostate Cancer.

Authors:  Wei Li; Zhe Lu; Dongqing Pan; Zejian Zhang; Hua He; Jiacheng Wu; Naixiong Peng
Journal:  J Oncol       Date:  2022-07-06       Impact factor: 4.501

6.  Comprehensive analysis of aerobic glycolysis-related genes for prognosis, immune features and drug treatment strategy in prostate cancer.

Authors:  Wei He; Xiang He; Enhui Li
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

7.  Targeting the MALAT1 gene with the CRISPR/Cas9 technique in prostate cancer.

Authors:  Soraya Ahmadi-Balootaki; Abbas Doosti; Mojtaba Jafarinia; Hamed Reza Goodarzi
Journal:  Genes Environ       Date:  2022-09-26

8.  A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer.

Authors:  Ning Shao; Hong Tang; Yuanyuan Mi; Yao Zhu; Fangning Wan; Dingwei Ye
Journal:  Oncoimmunology       Date:  2020-06-01       Impact factor: 8.110

9.  Proteomics score: a potential biomarker for the prediction of prognosis in non-small cell lung cancer.

Authors:  Jie Peng; Jing Zhang; Dan Zou; Wuxing Gong
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.